Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas

Contrast Media and Molecular Imaging

Volumn 7, Issue 2, 2012, Pages 160-166

  Brom, Maarten ^a   Joosten, Lieke ^a   Oyen, Wim J G ^a   Gotthardt, Martin ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Agonist; Antagonist; Exendin; GLP 1; Insulinoma

Indexed keywords

EXENDIN (3-39); EXENDIN 3; EXENDIN 4; GLUCAGON LIKE PEPTIDE; LYSINE; PENTETIC ACID; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CONTROLLED STUDY; IC 50; IN VITRO STUDY; IN VIVO STUDY; INSULINOMA; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CONFIDENCE INTERVALS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; GLUCAGON-LIKE PEPTIDE 1; INHIBITORY CONCENTRATION 50; INSULINOMA; KINETICS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; PEPTIDES; RADIOPHARMACEUTICALS; RATS; STAINING AND LABELING; TISSUE DISTRIBUTION; VENOMS;

EID: 84858722121     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.475     Document Type: Article

References (29)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24(4): 389-427.
2. Koenig JA, Edwardson JM. Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 1997; 18(8): 276-287.
3. Bodei L, Paganelli G, Mariani G. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. J Nucl Med 2006; 47(3): 375-377.
4. Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 2006; 47(3): 502-511.
5. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003; 24(1): 28-47.
6. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev 2003; 2(12): 999-1017.
7. Storch D, Behe M, Walter MA, Chen J, Powell P, Mikolajczak R, Macke HR. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0, Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005; 46(9): 1561-1569.
8. Breeman WA, Hofland LJ, de Jong M, Bernard BF, Srinivasan A, Kwekkeboom DJ, Visser TJ, Krenning EP. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 1999; 81(4): 658-665.
9. Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, Waser B, Cescato R, Reubi JC, Maecke HR. Evaluation of a 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 2009; 15(16): 5240-5249.
10. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, Reubi JC. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008; 49(2): 318-326.
11. Abd-Elgaliel WR, Gallazzi F, Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Hoffman TJ, Lever SZ. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjug Chem 2008; 19(10): 2040-2048.
12. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Macke HR, Reubi JC. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006; 103(44): 16436-16441.
13. Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 1997; 112(2): 583-590.
14. Joseph K, Stapp J, Reinecke J, Skamel HJ, Hoffken H, Benning R, Neuhaus C, Lenze H, Trautmann ME, Arnold R. [Receptor scintigraphy using 111In-pentetreotide in endocrine gastroenteropancreatic tumors]. Nuklearmedizin 1993; 32(6): 299-305.
15. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20(8): 716-731.
16. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imag 2003; 30(5): 781-793.
17. Gotthardt M, Fischer M, Naeher I, Holz JB, Jungclas H, Fritsch HW, Behe M, Goke B, Joseph K, Behr TM. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imag 2002; 29(5): 597-606.
18. Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, Kneifel S, Mihatsch MJ, Reubi JC, Macke HR, Christofori G. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007; 13(12): 3696-3705.
19. Wild D, Behe M, Wicki A, Storch D, Waser B, Gotthardt M, Keil B, Christofori G, Reubi JC, Macke HR. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006; 47(12): 2025-2033.
20. Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. New Engl J Med 2008; 359(7): 766-768.
21. Gotthardt M, Lalyko G, van Eerd-Vismale J, Keil B, Schurrat T, Hower M, Laverman P, Behr TM, Boerman OC, Goke B, Behe M. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regulat Pept 2006; 137(3): 162-167.
22. Raufman JP, Singh L, Eng J. Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. Description of exendin-3(9-39) amide, a specific exendin receptor antagonist. J Biol Chem 1991; 266(5): 2897-2902.
23. Waser B, Reubi JC. Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans. Eur J Nucl Med Mol Imag 2010; 38(6): 1054-1058.
24. Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther 1999; 288(2): 729-734.
25. Sleight AJ, Stam NJ, Mutel V, Vanderheyden PM. Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities. Biochem Pharmacol 1996; 51(1): 71-76.
26. Mukai E, Toyoda K, Kimura H, Kawashima H, Fujimoto H, Ueda M, Temma T, Hirao K, Nagakawa K, Saji H, Inagaki N. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging. Biochem Biophys Res Commun 2009; 389(3): 523-526.
27. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imag 37(7): 1345-1355.
28. Waser B, Reubi JC. Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans. Eur J Nucl Med Mol Imag 2011; 38(6): 1054-1058.
29. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 1992; 130(1): 167-178.